Avantor (AVTR): insider & executive buying
Avantor · Health Care · ref. ETF XLV · price $14.61
In short — 3 insiders bought Avantor over ~6 months (3 buys, total $1.3M, latest May 8, 26) — cluster buy. Public Form 4 data, informative (not a performance signal).
Are Avantor's executives buying their own shares? Here are the disclosed insider buys over the last 6 months — a transparency data point, not an outperformance signal.
📈 1-year price
$14.61+10.6% over range
Aug 28, 25low $7.41 · high $15.6Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
14% recommend buying · 7 analysts
Latest insider buys on Avantor
| Date | Insider | Role | Shares | Amount |
|---|---|---|---|---|
| May 8, 26 | Lucier Gregory T | Dir | 10,000 | $83k |
| May 1, 26 | Dingemans Simon | Dir | 25,000 | $204k |
| Mar 10, 26 | Mehra Sanjeev K | Dir | 125,000 | $1.0M |
⚠️ Open-market buys reported to the SEC (Form 4). Transparency data, not advice nor an outperformance signal (our backtests show no reliable edge).
Frequently asked questions
Have Avantor's executives bought shares recently?
3 Avantor insider(s) bought $1.3M over ~6 months (latest May 8, 26). A buy shows confidence, but our backtests show no performance edge.
Is insider buying a good signal for AVTR?
It's useful transparency data, but NOT a performance guarantee: our historical tests show no reliable edge from following insider buys. Cross-check with fundamentals and analyst views.
Where does this data come from?
From Form 4 filings with the SEC (mandatory for officers and 10%+ holders), aggregated and refreshed regularly.
💬 A question about Avantor? The JPI assistant answers using our backtest data.